Liquid Biopsy MRD Utilization and Market Landscape Study

We are conducting internal research to understand the current liquid biopsy minimal residual disease (MRD) and monitoring test utilization, as well as the overall market landscape. We are scheduling paid consultations between 30-45 minutes to speak with individuals that are knowledgeable in the MRD/monitoring assay utilization and MRD/ monitoring market landscape. ‍